NewsResearch
After the First Phase 3 Cancer Vaccine Win, What Happens Next?
The melanoma vaccine result was presented at the ESMO 2026 meeting in Madrid. STAT reports a 42% lower risk of recurrence or death. Here is what that number means, what it does not tell you, and what researchers say may come next.
Original commentary from the Cancer Explained editorial team.
Review status: AI-assisted, source checked. Not reviewed by a clinician. How we check pages
Sources last checked .
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
What is new
In August, Merck and Moderna said a trial of a personalized mRNA cancer vaccine met its main goal. In October 2026 the result was presented at the European Society for Medical Oncology (ESMO) meeting in Madrid.
STAT News reports that adding the vaccine, called intismeran, to Keytruda (pembrolizumab) cut the risk of the melanoma coming back or the person dying by 42%, compared with Keytruda alone. STAT calls it the first successful phase 3 cancer vaccine trial.
We have not seen the full data. The details below come from STAT's report, and part of that article is behind a paywall.
What "42% lower risk" means
It is a relative number. It compares the two groups during the trial. It does not say that 42 out of 100 people were helped.
To know how big the benefit is for a person, you also need the absolute numbers: how many people in each group had melanoma return, and over how long. We could not confirm those from the sources we could read.
It also does not predict what will happen to any one person. It describes a group.
Who was studied
The trial enrolled people whose melanoma had been fully removed by surgery. In our earlier report on the announcement, the stage range was IIB to IV. The vaccine is made for each person from their own tumor.
If your melanoma was removed, your follow-up plan and any treatment after surgery are still set by your own team. Nothing in this report changes that.
What researchers say may come next
STAT reports that researchers are now looking at other tumor types. One researcher it quotes, James Larkin, said that in principle this kind of approach may work in other cancers.
That is a hope, not a result. Trials in other cancers have their own timelines, and some will not work. Another researcher, Vinod Balachandran, described the history of cancer vaccines as a long, 100-year stretch of mostly failures. This success is the first of its kind in phase 3.
What this does not mean
- It is not approved. The treatment is not available outside a clinical trial. Regulators have not approved it.
- It does not mean cancer vaccines make cancer go away for good. This one is given with an existing drug, and the trial measured how long people stayed free of melanoma.
- We do not know the side effects from the sources we could read. Keytruda alone can cause immune side effects, and the combination may add more. Ask your team about them.
Questions to ask your care team
- Given my stage, what is my chance that melanoma comes back with the treatment I am having now?
- Am I a candidate for any trial of a personalized vaccine?
- If I joined a trial, what would change about my visits, scans and travel?
Sources
- STAT News, "After a cancer vaccine's first success, the race is on to expand the impact," October 25, 2026.
- Merck and Moderna, INTerpath-001 topline announcement.
- National Cancer Institute, Cancer Treatment Vaccines.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Melanoma. The information below is general, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn more about melanoma
A news story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.